Today in the News
SEE OTHER BRANDS

The latest news on global issues

Today in the News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in the News.

Press releases published on June 15, 2025

XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)

XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)

New York, June 15, 2025 (GLOBE NEWSWIRE) -- Surprises are common in the crypto sphere but an unprecedented 1,000% surge in XRP Ledger’s payment volume hits different. It speaks of marvelous things to come. That’s why investors are scrambling to position …

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Communiqué :  Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

SAN FRANCISCO, June 15, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and …

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …

Reputation Pros Named Best Online Reputation Management Company of 2025 by Modern Luxury Magazine

Reputation Pros Named Best Online Reputation Management Company of 2025 by Modern Luxury Magazine

Miami, FL, June 15, 2025 (GLOBE NEWSWIRE) -- Modern Luxury Magazine today announced Reputation Pros as the best online reputation management company of 2025 in its annual Best Online Reputation Management Companies feature, published online in May 2025. …

ZA Miner Introduces Intelligent Cloud Mining Platform for 2025, Capitalizing on Bitcoin Halving Momentum and Market Growth

ZA Miner Introduces Intelligent Cloud Mining Platform for 2025, Capitalizing on Bitcoin Halving Momentum and Market Growth

London, UK, June 15, 2025 (GLOBE NEWSWIRE) -- ZA Miner Introduces Intelligent Cloud Mining Platform for 2025, Capitalizing on Bitcoin Halving Momentum and Market Growth  Platform leverages simplified mining contracts, smart infrastructure, and accessible …

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. (NASDAQ: EGBN) resulting from allegations that …

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that …

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle- …

Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap

Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap

TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch …

XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token

XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token

SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) -- Vaultro Finance has just announced a landmark achievement in its public sale of the native utility token VLT. The $VLT presale Round has now achieved a 50% sale milestone, marking a pivotal moment in the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service